TY  - JOUR
AU  - Stacchiotti, Silvia
AU  - Mir, Olivier
AU  - Le Cesne, Axel
AU  - Vincenzi, Bruno
AU  - Fedenko, Alexander
AU  - Maki, Robert G
AU  - Somaiah, Neeta
AU  - Patel, Shreyaskumar
AU  - Brahmi, Mehedi
AU  - Blay, Jean Y
AU  - Boye, Kjetil
AU  - Sundby-Hall, Kirsten
AU  - Gelderblom, Hans
AU  - Hindi, Nadia
AU  - Martin-Broto, Javier
AU  - Kosela, Hanna
AU  - Rutkowski, Piotr
AU  - Italiano, Antoine
AU  - Duffaud, Florence
AU  - Kobayashi, Eisuke
AU  - Casali, Paolo G
AU  - Provenzano, Salvatore
AU  - Kawai, Akira
PY  - 2017
DO  - 10.1634/theoncologist.2017-0161
UR  - http://hdl.handle.net/10668/11453
T2  - The oncologist
AB  - Alveolar soft part sarcoma (ASPS) is an exceedingly rare and orphan disease, without active drugs approved in the front line. Pazopanib and trabectedin are licensed for sarcoma treatment from second-line, but very little and contradictory data are...
LA  - en
PB  - Oxford University Press
KW  - Alveolar soft part sarcoma
KW  - Chemotherapy
KW  - Pazopanib
KW  - Sarcoma
KW  - Trabectedin
KW  - Adult
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Female
KW  - Follow-Up Studies
KW  - Humans
KW  - Indazoles
KW  - Male
KW  - Middle Aged
KW  - Prognosis
KW  - Pyrimidines
KW  - Retrospective Studies
KW  - Sarcoma, Alveolar Soft Part
KW  - Sulfonamides
KW  - Survival Rate
KW  - Trabectedin
TI  - Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma.
TY  - research article
VL  - 23
ER  -